NEW YORK (GenomeWeb News) – Empire Genomics today announced it has received a Phase I SBIR grant from the National Cancer Institute to develop a genomic companion diagnostic test for multiple myeloma.

It is the first SBIR grant for Buffalo, NY-based Empire. The firm plans to use the funds to further develop its licensed technology for use in predicting multiple myeloma patient response to therapeutic treatments.

The grant lasts through October. According to the National Institutes of Health's grants database, the grant is for $142,432.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.